Lung Cancer Europe

Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC

International Association for the Study of Lung Cancer shared a post on LinkedIn:

“This study from Tavernari et al. highlights the need to identify uncommon mutations of EGFR to inform therapeutic decisions.

Given the tobacco-related molecular signatures and high tumor mutational burden associated with this subgroup, further investigation is warranted.”

Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC: A Brief Report

Authors: Daniele Tavernari, Alfredo Addeo, et al.

Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC

More posts featuring International Association for the Study of Lung Cancer.

cancer EGFR IASLC International Association for the Study of Lung Cancer Lung cancer NSCLC OncoDaily Oncology